医学
前列腺切除术
前列腺癌
回顾性队列研究
活检
逻辑回归
前列腺
放射科
泌尿科
癌症
外科
内科学
作者
Alessio Paladini,Giovanni Cochetti,Alexandre Colau,M. Mouton,Sara Ciarletti,Graziano Felici,Giuseppe Maiolino,Federica Balzarini,Philippe Sèbe,Ettore Mearini
出处
期刊:Current Oncology
[Multidisciplinary Digital Publishing Institute]
日期:2022-09-22
卷期号:29 (10): 6826-6833
被引量:7
标识
DOI:10.3390/curroncol29100538
摘要
Increased diagnoses of silent prostate cancer (PCa) have led to overtreatment and consequent functional side effects. Focal therapy (FT) applies energy to a prostatic index lesion treating only the clinically significant PCa focus. We analysed the potential predictive factors of FT failure. We collected data from patients who underwent robot-assisted radical prostatectomy (RARP) in two high-volume hospitals from January 2017 to January 2020. The inclusion criteria were: one MRI-detected lesion with a Gleason Score (GS) of ≤7, ≤cT2a, PSA of ≤10 ng/mL, and GS 6 on a random biopsy with ≤2 positive foci out of 12. Potential oncological safety of FT was defined as the respect of clinicopathological inclusion criteria on histology specimens, no extracapsular extension, and no biochemical, local, or metastatic recurrence within 12 months. To predict FT failure, we performed uni- and multivariate logistic regression. Sixty-seven patients were enrolled. The MRI index lesion median size was 11 mm; target lesions were ISUP grade 1 in 27 patients and ISUP grade 2 in 40. Potential FT failure occurred in 32 patients, and only the PSA value resulted as a predictive parameter (p < 0.05). The main issue for FT is patient selection, mainly because of multifocal csPCa foci. Nevertheless, FT could represent a therapeutic alternative for highly selected low-risk PCa patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI